[cs_content][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_inset=”0px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_inset=”0px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 45px 0px 20px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][cs_text class=”cs-ta-center” style=”margin-bottom: 20px;”]

Medulloblastoma

[/cs_text][cs_text]Medulloblastoma is a type of brain tumor. A brain tumor begins when healthy cells in the brain change and grow out of control, forming a mass. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.

The brain and spinal column make up the central nervous system (CNS), where all vital functions are controlled, including thought, speech, and body strength. Medulloblastoma begins in different cells in the cerebellum, which is the back of the brain. The cerebellum controls body movement and coordination.

Source: cancer.net.[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_inset=”0px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_inset=”0px” separator_bottom_angle_point=”50″ class=”cs-hide-xl cs-hide-lg cs-hide-md cs-hide-sm cs-hide-xs” style=”margin: 0px;padding: 0 0px 10px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][cs_text class=”cs-ta-center”]

Relevant Videos

[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_inset=”0px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_inset=”0px” separator_bottom_angle_point=”50″ class=”cs-hide-xl cs-hide-lg cs-hide-md cs-hide-sm cs-hide-xs” style=”margin: 0px;padding: 0 0px 20px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ style=”padding: 0px;”][x_video_embed no_container=”false” type=”16:9″][/x_video_embed][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ style=”padding: 0px;”][x_video_embed no_container=”false” type=”16:9″][/x_video_embed][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_inset=”0px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_inset=”0px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 0 0px 30px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][cs_text class=”cs-ta-center”]

Medulloblastoma Trials

[/cs_text][x_prompt type=”left” title=”ONC-403-001″ message=”A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma OPEN” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT02748135″ href_title=”” target=”blank”][x_prompt type=”left” title=”NMTRC009″ message=”Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers CLOSED” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT02162732″ href_title=”” target=”blank”][x_prompt type=”left” title=”V0706″ message=”A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma OPEN TO THE FOLLOWING GROUPS: RELAPSE NEUROBLASTOMA MEDULLOBLASTOMA” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT00601003″ href_title=”” target=”blank”][x_prompt type=”left” title=”NMTRC008″ message=”A Feasibility Trial using Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancer CLOSED” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT01802567″ href_title=”” target=”blank”][x_prompt type=”left” title=”TPI-287-11″ message=”A Phase 1 Trial of TPI 287 as a Single Agent and in Combination with Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma CLOSED” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT00867568″ href_title=”” target=”blank”][x_prompt type=”left” title=”NMTRC004″ message=”A Phase I/II Trial of TPI 287 in Patients with Refractory or Recurrent Neuroblastoma and Medulloblastoma CLOSED” button_text=”ClinicalTrials.gov” button_icon=”chain” circle=”false” href=”https://clinicaltrials.gov/ct2/show/NCT01483820″ href_title=”” target=”blank”][/cs_column][/cs_row][/cs_section][/cs_content]